Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewNBOH-2C-CN hydrochloride is a high affinity, selective 5-HT2A agonist (Ki = 1.3 nM). Exhibits 100-fold selectivity for 5-HT2A over 5-HT2C. Elicits head twitch behavior in mice.
分子量 | 348.82 |
公式 | C18H20N2O3.HCl |
储存 | Desiccate at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 1539266-32-4 |
PubChem ID | 90489019 |
InChI Key | JQVAEIIIMVMJBO-UHFFFAOYSA-N |
Smiles | OC(C=CC=C2)=C2CNCCC1=C(OC)C=C(C#N)C(OC)=C1.Cl |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 3.49 | 10 温和加热 | |
DMSO | 34.88 | 100 |
以下数据基于产品分子量 348.82。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.87 mL | 14.33 mL | 28.67 mL |
5 mM | 0.57 mL | 2.87 mL | 5.73 mL |
10 mM | 0.29 mL | 1.43 mL | 2.87 mL |
50 mM | 0.06 mL | 0.29 mL | 0.57 mL |
参考文献是支持产品生物活性的出版物。
Hansen et al (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS.Chem.Neurosci. 5 243 PMID: 24397362
Fantegrossi et al (2014) Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology (Berl.) 232 1039 PMID: 25224567
Jensen et al (2017) Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist. J.Pharmacol.Exp.Ther 361 441 PMID: 28360333
Jensen et al (2020) The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [ 3H]25CN-NBOH. Biochem.Pharmacol. 177 113979 PMID: 32298690
If you know of a relevant reference for NBOH-2C-CN hydrochloride, please let us know.
关键词: NBOH-2C-CN hydrochloride, NBOH-2C-CN hydrochloride supplier, serotonin, potent, selective, high, affinity, 5-ht, 5-ht2a, agonists, receptors, hallucinogen-like, 25CN-NBOH, 5-HT2A, Receptors, 5171, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 NBOH-2C-CN hydrochloride 的部分引用包括:
Hongyan et al (2022) Bimodal modulation of short-term motor memory via dynamic sodium pumps in a vertebrate spinal cord. Curr Biol 32 1038-1048.e2 PMID: 35104440
Wieland B et al (2020) Serotonin Receptor 2A Activation Promotes Evolutionarily Relevant Basal Progenitor Proliferation in the Developing Neocortex. Neuron 108 1113-1129.e6 PMID: 33080227
您是否知道使用了 Tocris NBOH-2C-CN hydrochloride 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review NBOH-2C-CN hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.